Capricor and Nippon Shinyaku partner for DMD therapy distribution in Japan
Pharmaceutical Technology
FEBRUARY 17, 2023
The data from our recently announced 18-month HOPE-2 open-label extension study showed evidence of disease modification and showed statistically significant differences in the Performance of the Upper Limb (PUL).” “CAP-1002 has shown clinical benefits for cardiac and skeletal muscle myopathy, which few therapies have demonstrated.
Let's personalize your content